Bevacizumab in the treatment of breast cancer: rationale and current data.
about
Human epidermal growth factor receptor 2 positive (HER2+) metastatic breast cancer: how the latest results are improving therapeutic optionsDetermination of breast cancer response to bevacizumab therapy using contrast-enhanced ultrasound and artificial neural networksHEXIM1 modulates vascular endothelial growth factor expression and function in breast epithelial cells and mammary gland.Nonlinear modelling of cancer: bridging the gap between cells and tumoursMetastatic clear cell carcinoma of the kidney: therapeutic role of bevacizumabDevelopment of a questionnaire (EORTC module) to measure quality of life in patients with cholangiocarcinoma and gallbladder cancer, the EORTC QLQ-BIL21.Personalized drug combinations to overcome trastuzumab resistance in HER2-positive breast cancer.Combination treatment with HER-2 and VEGF peptide mimics induces potent anti-tumor and anti-angiogenic responses in vitro and in vivoMolecular ultrasound imaging using a targeted contrast agent for assessing early tumor response to antiangiogenic therapyTargeting angiogenesis in cancer: clinical development of bevacizumab.Combined vaccination with HER-2 peptide followed by therapy with VEGF peptide mimics exerts effective anti-tumor and anti-angiogenic effects in vitro and in vivo.Vascular endothelial growth factor pharmacogenetics: a new perspective for anti-angiogenic therapy.The prevention and management of distant metastases in women with breast cancer.Management of venous thromboembolism in patients with cancer: role of dalteparin.Molecular targeted therapies for breast cancer treatment.The incidence and risk of venous thromboembolism associated with cancer and nonsurgical cancer treatment.High-circulating Tie2 Is Associated With Pathologic Complete Response to Chemotherapy and Antiangiogenic Therapy in Breast Cancer.Breast tumor cell TACE-shed MCSF promotes pro-angiogenic macrophages through NF-κB signaling.Antiangiogenic activity of BAI1 in vivo: implications for gene therapy of human glioblastomas.Impact of chemotherapy on thrombin generation and on the protein C pathway in breast cancer patients.Therapy for Cancer: Strategy of Combining Anti-Angiogenic and Target Therapies.Vasohibin-1 as a potential predictor of aggressive behavior of ductal carcinoma in situ of the breast.
P2860
Q26777681-8FFEEB8A-1BAC-4DCA-AC0D-15B4F9FD4301Q30475052-2FB2D37C-4E76-4349-BB74-8082111BAA18Q33940674-B55D04C9-5AC4-434A-B721-F63106A07F67Q34090411-9F1AC5D3-E451-40FE-BAF7-72D3354EAE32Q34417804-8410877A-4447-4856-AB07-B6FD78B07EA6Q34627921-A13BDAC2-AEED-4CBE-AEB0-67609CE08B5EQ34664129-63BB9AB6-D0E4-4079-B69B-0C09B6E61474Q34787422-9BE3BA44-CA4B-4CC4-A7C6-EE68455B7CDFQ36297117-2BD97AB4-2E8B-485B-B452-82B8865E60B5Q36303846-EA5B3854-59C8-45E1-9109-95FBF66D4A1DQ36388501-99462AA4-66AA-4167-86EE-BFC25F689883Q36691776-5E263DE0-5943-4AA6-A96A-9DF52730F5E4Q36761407-A72B595C-535A-459A-A55C-4A01CD6A2ABCQ36812767-CB438527-30FD-464D-B3D3-B9D6514C00E9Q36955065-BB5CE52E-8F7A-4FBE-A16E-DED8C4FB3E5FQ37374557-8C2FCBF9-9B85-4DCC-853E-EA4A8EF89F34Q38435332-28CD2B27-0087-4132-B8D2-CFC0721C19ECQ39066460-D5393771-6343-40E9-98B0-0435151BD95EQ40358748-6D8170E9-F228-4D6A-88B6-B81663F6C226Q42745163-F416138C-D24B-4FE2-BA67-4A2A969D2879Q47134647-436F0613-A30B-4BB3-9DCF-F2FFFBCF5A27Q51547813-B7E2AE25-D4F6-45BB-9D46-62AC9D7A73CC
P2860
Bevacizumab in the treatment of breast cancer: rationale and current data.
description
2004 nî lūn-bûn
@nan
2004 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Bevacizumab in the treatment of breast cancer: rationale and current data.
@ast
Bevacizumab in the treatment of breast cancer: rationale and current data.
@en
type
label
Bevacizumab in the treatment of breast cancer: rationale and current data.
@ast
Bevacizumab in the treatment of breast cancer: rationale and current data.
@en
prefLabel
Bevacizumab in the treatment of breast cancer: rationale and current data.
@ast
Bevacizumab in the treatment of breast cancer: rationale and current data.
@en
P1433
P1476
Bevacizumab in the treatment of breast cancer: rationale and current data.
@en
P2093
Hope S Rugo
P356
10.1634/THEONCOLOGIST.9-SUPPL_1-43
P478
P577
2004-01-01T00:00:00Z